NORDHEALTH |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.9 NOK | -0.30% |
|
+1.23% | +32.66% |
| May. 14 | Transcript : Nordhealth AS, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Nordhealth AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 320.8 | 169.7 | 174.6 | 221.4 | - |
| Enterprise Value (EV) 1 | 247.8 | 130.4 | 152.4 | 198.4 | 194.2 |
| P/E ratio | -67.8 x | -12 x | -15.7 x | -25.5 x | -140 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 15.8 x | 10.3 x | 4.74 x | 4.86 x | 4.27 x |
| EV / Revenue | 12.2 x | 7.91 x | 4.14 x | 4.35 x | 3.75 x |
| EV / EBITDA | 131 x | -21.8 x | -122 x | 92.7 x | 22.7 x |
| EV / FCF | 113,160,911 x | - | - | - | - |
| FCF Yield | 0% | - | - | - | - |
| Price to Book | 2.8 x | 1.71 x | 2.11 x | 3.11 x | 3.18 x |
| Nbr of stocks (in thousands) | 80,000 | 80,192 | 79,045 | 79,045 | - |
| Reference price 2 | 4.010 | 2.116 | 2.209 | 2.802 | 2.802 |
| Announcement Date | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.68 | 20.3 | 16.48 | 36.82 | 45.58 | 51.86 |
| EBITDA 1 | - | 1.895 | -5.975 | -1.248 | 2.14 | 8.56 |
| EBIT 1 | - | -4.458 | -14.68 | -11.39 | -9.63 | -3.06 |
| Operating Margin | - | -21.96% | -89.03% | -30.92% | -21.13% | -5.9% |
| Earnings before Tax (EBT) 1 | - | -4.646 | -14.06 | -10.81 | -8.92 | -1.91 |
| Net income 1 | 1.928 | -4.731 | -14.16 | -11.13 | -9.04 | -1.91 |
| Net margin | 15.2% | -23.31% | -85.89% | -30.23% | -19.83% | -3.68% |
| EPS 2 | - | -0.0591 | -0.1770 | -0.1408 | -0.1100 | -0.0200 |
| Free Cash Flow | - | 2.19 | - | - | - | - |
| FCF margin | - | 10.79% | - | - | - | - |
| FCF Conversion (EBITDA) | - | 115.57% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 6/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 73 | 39.2 | 22.2 | 23.1 | 27.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 2.19 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -13.3% | -12.3% | -11.7% | -2.68% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 1.430 | 1.230 | 1.050 | 0.9000 | 0.8800 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 3.38 | - | - | - | - |
| Capex / Sales | - | 16.64% | - | - | - | - |
| Announcement Date | 6/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.802
EUR
Average target price
3.631
EUR
Spread / Average Target
+29.61%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.66% | 241M | |
| -5.50% | 30.25B | |
| +36.17% | 9.47B | |
| +31.81% | 4.33B | |
| -36.88% | 2.49B | |
| -6.48% | 1.66B | |
| -23.84% | 1.27B | |
| -42.92% | 972M | |
| -3.96% | 885M | |
| -50.69% | 687M |
- Stock Market
- Equities
- NORDH Stock
- Financials Nordhealth
